Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure — Stella
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations(14 sites)
United States
Hartford Health Care, Hartford, Connecticut
North Shore University Health, Evanston, Illinois
Brigham and Woman's Hospital, Boston, Massachusetts
Henry Ford Health Care, Detroit, Michigan
Northwell Health System, New York, New York
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Belgium
University of Leuven, Leuven, Belgium
Canada
Winnipeg Health Sciences Center, Winnipeg, Manitoba